Skip to main content
Top
Published in: European Journal of Epidemiology 5/2020

Open Access 01-05-2020 | Bronchial Asthma | COVID-19

Burden and prevalence of prognostic factors for severe COVID-19 in Sweden

Authors: Katalin Gémes, Mats Talbäck, Karin Modig, Anders Ahlbom, Anita Berglund, Maria Feychting, Anthony A. Matthews

Published in: European Journal of Epidemiology | Issue 5/2020

Login to get access

Abstract

The World Health Organization and European Centre for Disease Prevention and Control suggest that individuals over the age of 70 years or with underlying cardiovascular disease, cancer, chronic obstructive pulmonary disease, asthma, or diabetes are at increased risk of severe COVID-19. However, the prevalence of these prognostic factors is unknown in many countries. We aimed to describe the burden and prevalence of prognostic factors of severe COVID-19 at national and county level in Sweden. We calculated the burden and prevalence of prognostic factors for severe COVID-19 based on records from the Swedish national health care and population registers for 3 years before 1st January 2016. 9,624,428 individuals were included in the study population. 22.1% had at least one prognostic factor for severe COVID-19 (2,131,319 individuals), and 1.6% had at least three factors (154,746 individuals). The prevalence of underlying medical conditions ranged from 0.8% with chronic obstructive pulmonary disease (78,516 individuals) to 7.4% with cardiovascular disease (708,090 individuals), and the county specific prevalence of at least one prognostic factor ranged from 19.2% in Stockholm (416,988 individuals) to 25.9% in Kalmar (60,005 individuals). We show that one in five individuals in Sweden is at increased risk of severe COVID-19. When compared with the critical care capacity at a local and national level, these results can aid authorities in optimally planning healthcare resources during the current pandemic. Findings can also be applied to underlying assumptions of disease burden in modelling efforts to support COVID-19 planning.
Appendix
Available only for authorised users
Literature
3.
go back to reference Riou J, et al. Adjusted age-specific case fatality ratio during the COVID-19 epidemic in Hubei, China, January and February 2020. medRxiv, 2020: p. 2020.03.04.20031104. Riou J, et al. Adjusted age-specific case fatality ratio during the COVID-19 epidemic in Hubei, China, January and February 2020. medRxiv, 2020: p. 2020.03.04.20031104.
4.
go back to reference Zheng Y-Y, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–60.CrossRef Zheng Y-Y, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–60.CrossRef
5.
go back to reference Chen T, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.CrossRef Chen T, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.CrossRef
6.
go back to reference Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef
7.
go back to reference Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.CrossRef Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.CrossRef
8.
go back to reference Zhao X, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv, 2020: p. 2020.03.17.20037572. Zhao X, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv, 2020: p. 2020.03.17.20037572.
9.
go back to reference Ferguson N, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. 2020, WHO Collaborating Centre for Infectious Disease Modelling MRC Centre for Global Infectious Disease Analysis Abdul Latif Jameel Institute for Disease and Emergency Analytics Imperial College London. London. Ferguson N, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. 2020, WHO Collaborating Centre for Infectious Disease Modelling MRC Centre for Global Infectious Disease Analysis Abdul Latif Jameel Institute for Disease and Emergency Analytics Imperial College London. London.
10.
go back to reference Rocklov J. Covid-19 health care demand and mortality in Sweden in response to non-pharmaceutical (NPIs) mitigation and suppression scenarios. medRxiv, 2020: p. 2020.03.20.20039594. Rocklov J. Covid-19 health care demand and mortality in Sweden in response to non-pharmaceutical (NPIs) mitigation and suppression scenarios. medRxiv, 2020: p. 2020.03.20.20039594.
11.
go back to reference Lin Q, et al. A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action. Int J Infect Dis. 2020;93:211–6.CrossRef Lin Q, et al. A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action. Int J Infect Dis. 2020;93:211–6.CrossRef
12.
go back to reference Kucharski AJ, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis 2020. Kucharski AJ, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis 2020.
13.
go back to reference Ludvigsson JF, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67.CrossRef Ludvigsson JF, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67.CrossRef
14.
go back to reference Ludvigsson JF, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.CrossRef Ludvigsson JF, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.CrossRef
15.
go back to reference Ludvigsson JF, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31(2):125–36.CrossRef Ludvigsson JF, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31(2):125–36.CrossRef
16.
go back to reference Wettermark B, et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–35.CrossRef Wettermark B, et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–35.CrossRef
17.
go back to reference Barlow L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.CrossRef Barlow L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.CrossRef
19.
go back to reference Engholm G, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 6.0. 2014(Updated 2013 Dec 4; cited 2014 Mar 26). Engholm G, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 6.0. 2014(Updated 2013 Dec 4; cited 2014 Mar 26).
20.
go back to reference Eriksson B, et al. Pattern of cardiovascular comorbidity in COPD in a country with low-smoking prevalence: results from two-population-based cohorts from Sweden. COPD J Chronic Obstr Pulm Dis. 2018;15(5):454–63.CrossRef Eriksson B, et al. Pattern of cardiovascular comorbidity in COPD in a country with low-smoking prevalence: results from two-population-based cohorts from Sweden. COPD J Chronic Obstr Pulm Dis. 2018;15(5):454–63.CrossRef
21.
go back to reference Backman H, et al. Decreased prevalence of moderate to severe COPD over 15 years in northern Sweden. Respir Med. 2016;114:103–10.CrossRef Backman H, et al. Decreased prevalence of moderate to severe COPD over 15 years in northern Sweden. Respir Med. 2016;114:103–10.CrossRef
22.
go back to reference Lindberg A, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest. 2006;129(4):879–85.CrossRef Lindberg A, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest. 2006;129(4):879–85.CrossRef
23.
go back to reference Lötvall J, et al. West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma. Respir Res. 2009;10(1):94.CrossRef Lötvall J, et al. West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma. Respir Res. 2009;10(1):94.CrossRef
24.
go back to reference Backman H, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy. 2017;47(11):1426–35.CrossRef Backman H, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy. 2017;47(11):1426–35.CrossRef
25.
go back to reference Andersson T, et al. Prevalence and incidence of diabetes in Stockholm County 1990–2010. PLoS ONE. 2014;9(8):e104033.CrossRef Andersson T, et al. Prevalence and incidence of diabetes in Stockholm County 1990–2010. PLoS ONE. 2014;9(8):e104033.CrossRef
26.
go back to reference Gudbjörnsdottir S, et al. The National Diabetes Register in Sweden. An implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003;26(4):1270–6.CrossRef Gudbjörnsdottir S, et al. The National Diabetes Register in Sweden. An implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003;26(4):1270–6.CrossRef
27.
go back to reference Andersson T, Ahlbom A, Carlsson S. Diabetes prevalence in Sweden at present and projections for year 2050. PLoS ONE. 2015;10(11):e0143084.CrossRef Andersson T, Ahlbom A, Carlsson S. Diabetes prevalence in Sweden at present and projections for year 2050. PLoS ONE. 2015;10(11):e0143084.CrossRef
29.
go back to reference Brunström M. Hypertension, the Swedish Patient Register, and Selection BiasHypertension, the Swedish Patient Register, and Selection BiasLetters. JAMA Intern Med. 2016;176(6):862–3.CrossRef Brunström M. Hypertension, the Swedish Patient Register, and Selection BiasHypertension, the Swedish Patient Register, and Selection BiasLetters. JAMA Intern Med. 2016;176(6):862–3.CrossRef
31.
go back to reference Burki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020;21:629–30.CrossRef Burki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020;21:629–30.CrossRef
Metadata
Title
Burden and prevalence of prognostic factors for severe COVID-19 in Sweden
Authors
Katalin Gémes
Mats Talbäck
Karin Modig
Anders Ahlbom
Anita Berglund
Maria Feychting
Anthony A. Matthews
Publication date
01-05-2020
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 5/2020
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-020-00646-z

Other articles of this Issue 5/2020

European Journal of Epidemiology 5/2020 Go to the issue